Treatment of male stress urinary incontinence using autologous adipose-derived regenerative cells: Long-term efficacy and safety

Access this Article

Search this Article

Abstract

Objectives: To investigate the long‐term efficacy and safety of periurethral injection of autologous adipose‐derived regenerative cells for the treatment of post‐prostatectomy stress urinary incontinence. Methods: A total of 13 patients with persistent stress urinary incontinence after prostate surgery (radical prostatectomy, 10 patients; holmium laser enucleation of the prostate, three patients) underwent periurethral injection of adipose‐derived regenerative cells and were followed up for >4 years. A 24‐h pad test was carried out for four consecutive days in each evaluation period, and changes in the mean daily leakage volume during the 4 days from baseline to 60 months after treatment were evaluated. Results: The mean follow‐up period was 69 months (range 55–72 months). The mean leakage volume/24 h in all patients changed from 260.7 g to 152.7 g. Urinary incontinence progressively improved up to 12 months after treatment in 10 patients, who maintained improvement up to the final assessment, with the mean daily leakage volume decreasing from 281.5 g to 119.0 g (reduction rate 57.7%). The other three patients showed no improvement at 1 year and at the final assessment. After the perioperative period, significant adverse events or prostate‐specific antigen increase were not observed during long‐term follow up. Conclusions: The present findings suggest that periurethral injection of autologous adipose‐derived regenerative cells is a safe and feasible treatment modality with long‐term efficacy for patients with male stress urinary incontinence caused by urethral sphincter deficiency.ファイル公開:2020-03-03

Journal

  • International Journal of Urology

    International Journal of Urology 26(3), 400-405, 2019-03-03

    Wiley

Codes

  • NII Article ID (NAID)
    120006643296
  • Text Lang
    ENG
  • Article Type
    journal article
  • ISSN
    0919-8172
  • Data Source
    IR 
Page Top